Clinical trial
TH9507 in Patients With HIV-Associated Lipodystrophy
NCT00123253 · Theratechnologies, Industry · Completed
Key facts
| NCT number | NCT00123253 |
|---|---|
| Title | TH9507 in Patients With HIV-Associated Lipodystrophy |
| Official title | A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation |
| Lead sponsor | Theratechnologies, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, Lipodystrophy |
| Intervention type | Drug |
| Interventions | TH9507 |
| Enrollment | 412 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | Jul 22, 2005 |
| Last update posted | Nov 27, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: